Given that all of our models of chemotherapy resistance resulted in impaired JNK activation, this finding prompted us to investigate the potential for synergy between these BH3-mimetic drugs and standard-of-care chemotherapy drugs in both primary and resistant neuroblastoma cells. Here, MAPK8 is linked to neuroblastoma.